



HHS Public Access

Author manuscript

Clin Immunol. Author manuscript; available in PMC 2020 June 29.

Published in final edited form as:

Clin Immunol. 2019 March ; 200: 43–54. doi:10.1016/j.clim.2019.02.002.

Immune aging in diabetes and its implications in wound healing

J. Moura^{1,2,3}, P. Madureira^{3,4,5}, E.C. Leal¹, A.C. Fonseca¹, E. Carvalho^{1,6,7}

¹Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal

²INEB - Instituto Nacional de Engenharia Biomédica, University of Porto, Porto, Portugal.

³i3S - Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal.

⁴BMC – Instituto de Biologia Celular e Molecular, University of Porto, Porto, Portugal.

⁵Immunethp, Biocant Park, Cantanhede, Portugal.

⁶Instituto de Investigação Interdisciplinar, University of Coimbra, Coimbra, Portugal

⁷Department of Geriatrics, University of Arkansas for Medical Sciences and Arkansas Children's Research Institute, Little Rock, Arkansas, United States

Abstract

Immune systems have evolved to recognize and eliminate pathogens and damaged cells. In humans, it is estimated to recognize 10⁹ epitopes and natural selection ensures that clonally expanded cells replace unstimulated cells and overall immune cell numbers remain stationary.

But, with age, it faces continuous repertoire restriction and concomitant accumulation of primed cells. Changes shaping the aging immune system have bitter consequences because, as inflammatory responses gain intensity and duration, tissue-damaging immunity and inflammatory disease arise.

During inflammation, the glycolytic flux cannot cope with increasing ATP demands, limiting the immune response's extent. In diabetes, higher glucose availability stretches the glycolytic limit, dysregulating proteostasis and increasing T-cell expansion. Long-term hyperglycemia exerts an accumulating effect, leading to higher inflammatory cytokine levels and increased cytotoxic mediator secretion upon infection, a phenomenon known as diabetic chronic inflammation.

Here we review the etiology of diabetic chronic inflammation and its consequences on wound healing.

Keywords

Chronic inflammation; immune aging; diabetes; wound healing

CORRESPONDING AUTHOR: João Moura (jmouraalves@gmail.com).

Former affiliation: Centro de Neurociências e Biologia Celular (CNC), Universidade de Coimbra, Rua Larga, Faculdade de Medicina, Pólo I, 1º andar, 3004-504 Coimbra, Portugal.

Current affiliation: Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

INTRODUCTION

The immune system has evolved significantly from the rudimentary enzyme-based defense mechanisms we see in bacteria, to the structured and adaptive system we see in vertebrates. As pathogens have evolved to hide from the host's immunity, so did the immune system evolve to be able to recognize a plethora of antigenic motifs. This results in complex mechanisms that enable the immune system to adapt and memorize previous pathogen encounters. This continuous adaptation has led to the specialization of individual cells and tissues, which is coordinated to ensure that the potentially devastating effect of the immune response is not unleashed upon healthy tissue, before, during or after pathogen infection occurs.

However, the continuous adaptation of the immune system comes with a price. The recurrent exposure to foreign antigens leads to a state of chronic inflammatory that is characteristic of elder individuals and is now called inflammaging [1]. Recently it has been proposed that the major source of inflammatory stimuli is not exterior but comes from altered host cell proteins that are a consequence of damaged and/or dead cells and organelles, a phenomenon known as garb-aging [2].

Many theories on the mechanisms that drive inflammaging have been put forth. As with all aspects of aging, it is reasonable to expect that inflammaging also has many causes and their relative weight varies significantly between individuals, due to lifestyle, genetics and pathogen encounters.

Several reviews have discussed the similarities between inflammaging and the chronic inflammation observed in diabetic patients [3, 4]. Some have even proposed that inflammaging could be a therapeutic target in diabetic patients [5]. Nonetheless, we believe that no other diabetic complication would benefit more from targeting inflammaging than chronic Diabetic Foot Ulcerations (DFU). This belief is based on the profound impact that chronic inflammation has on the exacerbation of the immune response and consequent healing dysregulation [6], hence the need for this literature review.

In this review we argue that inflammaging is a physiological consequence of the evolution of the immune system towards a pathogen-specific response, that had to cope with many stress factors. These stress factors include increased longevity and consequent reduced thymic output, increased metabolic dysfunction, due to excessive caloric intake and alterations in skin/gut microbial ecology. In addition, in diabetic individuals, hyperglycemia and other factors increase the activation of various immune cells leading to inflammatory cytokine overexpression, as will be discussed in more detail below.

Ultimately, all these factors lead to an exacerbation of the chronic inflammation phenotype [7], causing most of the diabetes-associated complications, especially wound healing impairment, observed in some diabetic individuals.

We end this review by addressing possible therapeutic strategies targeted toward chronic inflammation, therefore substantially improving wound healing in chronic DFU patients.

I. INFLAMMAGING

Inflammaging was first proposed by Franceschi and colleagues [1] in the year 2000, and was defined as a “global reduction in the capacity to cope with a variety of stressors and a concomitant progressive increase in the proinflammatory status”. This theory proposes that continuous antigenic stress leads to a proinflammatory status which, upon reaching a threshold, hinders the immune response and promotes disability and disease.

This status is characterized by increased levels of circulating proinflammatory cytokines, specially Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)- α [8] and the accumulation of effector (CD28^{null}) T-cells on both CD4⁺ and CD8⁺ subsets [9]. These cells are known to have a pathogenic potential in a variety of immune disorders, including autoimmune diseases, chronic inflammatory diseases and immune deficiency [10]. We will not discuss in detail the mechanisms and effects of inflammaging on immunosenescence, as they have recently been thoroughly reviewed [11]. Instead, we will focus on the causes of inflammaging and its relation with the chronic low-grade inflammation observed in diabetic patients.

Persistent viral infections, specially by Cytomegalovirus (CMV), are one of the driving forces behind inflammaging [12]. In fact, in old individuals, CMV seropositivity directly correlates with a decrease in naïve T-cells and an increase in memory and effector T-cell phenotypes, with concomitant increase in IL-6 levels [13], as well as an accumulation of terminally differentiated NKG2C⁺ CD57⁺ Natural Killer (NK) cells [14]. CMV infection also plays a role in the development of type 1 diabetes [15]. Furthermore, a seroprevalence of anti-CMV IgG antibodies has been associated with Type 2 Diabetes Mellitus (T2DM) in middle-aged individuals [16]. Interestingly, high levels of the pro-inflammatory cytokines TNF- α , IL-1 and IL-6 are also observed in diabetic patients [17]. Furthermore, a decrease in naïve T-cells and an increase in memory and effector T-cell phenotypes has been associated with diabetes and is believed to cause wound healing impairment, observed in DFU patients [7].

Age-related changes in gut microbiome have also been described as a cause of inflammaging [18]. Among many other factors, age-related changes in dietary content have a significant impact on the gut microbiome [19], which modulates the host's immunity [20]. It is thus commonly accepted that poorer dietary content negatively impacts on morbidity and mortality, in old age [21]. On the other hand, changes in the gut microbiome are also associated with obesity [22] and T2DM [23]. In fact, recent evidence has even suggested that the gut microbiome can be a target for the treatment of T2DM [24].

Although the association between the gut microbiome and aging is, by far, the most extensively studied, evidence that other microbiomes also change with age and contribute to inflammaging is increasing. Aging-related changes in skin microbiome [25], bladder microbiome [26] and urinary tract microbiome [27] also have an impact in the immune system. Interestingly, changes in the urinary tract [27] and bladder [28] microbiome are also associated with T2DM. Recent studies have reported a significant reduction in diversity of the skin microbiome in diabetic patients [29]. The mechanism and the extent to which age or

diabetes associated changes in these microbiomes have an impact on inflammaging is still elusive, but data from ongoing longitudinal studies will surely give new insights into this topic.

Oxidative stress and inflammaging are intimately related [30]. It is known that aging and diabetes share important features that include oxidative stress and low-grade inflammation. In aging, as in the early stages of diabetes there is a persistent accumulation of oxidative damage in biomolecules, caused by Reactive Oxygen Species (ROS) produced in all cells, especially by mitochondria [31]. Mitochondria are the main producers and also the main targets of ROS since it damages mitochondrial DNA (mtDNA), leading to a vicious cycle of increased ROS production. The consequence is the increase of mtDNA mutations that accelerate aging [32, 33].

Cells have several antioxidant defense mechanisms that prevent ROS formation or neutralize ROS after being generated, including superoxide dismutase, catalase and glutathione reductase [34, 35]. When the concentration of ROS overwhelms the capacity of these mechanisms, oxidative stress damages biomolecules, such as DNA, proteins, lipids and other cellular components [36]. So, a balance between ROS levels and antioxidants is needed for proper cell function [36]. Interestingly, it was shown that the increase in diet antioxidants can improve immune function and reduce oxidative stress, thus, the association between the redox state and immune function influences overall fitness [37]. Experimental evidence shows that low ROS levels extend lifespan in diverse organisms [38, 39]. It has been reported that Endothelial Progenitor Cells (EPCs) of diabetic patients suffer oxidative stress-induced premature senescence [40, 41]. The senescence of several tissues, including the endothelium, showed an upregulation of p53 in diabetic animal models and *in vitro* systems [42–44]. These data have shown treatment with antioxidants prevents endothelial senescence ameliorating endothelial dysfunction [42]. Also, diabetic patients treated with antioxidant compounds show better immune and endothelial function [45]. Moreover, an alternative to antioxidant administration is the promotion of the cellular antioxidant defense capacity to restore the redox status and prevent diabetes or aging-related damage [46]. As an example, Caloric Restriction (CR), which has a well-established antiaging action, diminishes oxidative stress and age-related diseases [47, 48]. CR modulates several important inflammatory signaling pathways involved in aging and inflammation, such as mammalian Target Of Rapamycin (mTOR), Nuclear Factor (NF)- κ B and Mitogen Activated Protein Kinases (MAPK) [49] and attenuates the age-related upregulation of IL-1 β , IL-6, and TNF- α [47]. Moreover, sirtuins, a family of NAD⁺-dependent deacetylases with epigenetic modulating activity, can prevent vascular senescence by increasing antioxidant defense [50]. Resveratrol and synthetic sirtuin activators mimic CR by conferring the attenuation of low-grade inflammation, especially in obesity and T2DM models [51–53]. Aging and diabetes lead to a reduced ability to preserve the cellular or system redox state resulting in a functional loss and an increase in oxidative stress which can lead to an increased production of proinflammatory cytokines that lead to a low grade chronic inflammatory condition, creating a vicious circle [54].

Even though the major driving force for inflammaging is probably external, recent evidence has suggested that cellular debris, organelles and other cellular components are a significant

source of inflammaging [2]. Millions of cells die every day in our body and their contents can actively trigger an inflammatory response [55]. Some of these responses appear to be driven by stimulation of pattern recognition receptors [56] on dendritic cells or through various low molecular weight molecules that stimulate phagocytes. These have recently been named “find-me” signals [57].

Protein homeostasis, known as proteostasis, involves the activation of the Unfolded Protein Response (UPR), the Endoplasmic Reticulum-Associated protein Degradation (ERAD)/ Ubiquitin-Proteasome System (UPS) and different types of autophagy [58]. A direct link between aging and a decline in proteostasis has been established [58–61] and protein misfolding seems to be a major contributor to tissue functional decline during aging [62]. For instance, the high proteasome activity found in centenarians may be one of the reasons for their healthy ageing, because proteasome degrades small damaged proteins [63]. Moreover, autophagy degrades unwanted long-lived proteins, protein aggregates and damaged or functionally redundant organelles and parts of organelles and there are many studies relating increased autophagy and a long life [64]. Moreover, Meijer and Codogno suggest that insulin resistance is an adaptive response to increased autophagy that will prolong life [65]. In fact, loss of proteostasis with age leads to the accumulation of dysfunctional proteins and protein aggregates that are found in almost all tissues of aged organisms [66]. Furthermore, increasing evidence suggests that many age-related pathologies, such as neurodegenerative diseases [67, 68], dementia [69] and osteoporosis [70], are associated with defects in proteostasis, as recently reviewed [71–73]. In addition, calorie restriction, which activates autophagy, provides protection against age-related diseases [65]. Interestingly, these pathologies and defects in proteostasis are associated with chronic inflammation [73–77].

Since the possible causes of inflammaging are also involved in the pathophysiology of diabetes, it is important to understand the relations between inflammaging and the chronic inflammation observed in diabetic patients.

II. CHRONIC INFLAMMATION IN OBESITY AND DIABETES

Basal low-grade inflammation in obese and diabetic patients has multiple causes and multiple consequences (Figure 1). In fact, immune cells, such as macrophages, dendritic cells and T cells usually infiltrate the adipose tissue of obese individuals and, as a result, adipose tissue secretes excess of free fatty acids and inflammatory cytokines.

The metaflammation theory, one of the most exciting new theories in the field of diabetes, put forth by Gokhan S Hotamisligil in 2006, links high nutrient intake and obesity with chronic inflammation [78]. In particular, chronic high-fat diet generates a low-grade inflammatory response, most notably through the Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing (NLRP)3 inflammasome [79], in tissues where free fatty acids reach the highest concentrations, such as the liver [80] and the adipose tissue [81]. More important, silencing NLRP3 can stop high fat diet induced chronic inflammation in animal models [82]. Moreover, damage to adipocytes and hepatocytes due to high fatty acid content leads to cell death that, in turn, is an additional source of

inflammation [83]. There are many studies relating dysfunctional proteostasis and inflammation in different types of diseases [84]. Some studies demonstrated an increased activation of the UPR in diabetic and obese patients and that ER stress has a role in insulin resistance in obesity and T2DM [85].

The endoplasmic reticulum (ER) is involved in calcium homeostasis, in the synthesis and folding of secreted and transmembrane proteins and in lipid biosynthesis. UPR, ERAD and autophagy are essential to maintain ER homeostasis [86, 87]. Intracellular stress, including the accumulation of fatty acids or cholesterol, bacterial toxins and proinflammatory cytokines, can lead to the accumulation of misfolded or unfolded proteins inside the ER, known as ER stress. This can activate one to three branches of the UPR, starting with Inositol-Requiring Enzyme (IRE)1 α , Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK) and Activating Transcription Factor (ATF)6, in order to preserve ER homeostasis [88–91]. Highly secretory cells, such as interferon-producing plasmacytoid dendritic cells, Paneth cells or B cells, are very dependent of the UPR for their correct differentiation and function [89, 92]. On the other hand, an excessive or prolonged ER stress can lead to the activation of apoptotic pathways [88]. The presence of apoptotic bodies can induce inflammation [93].

Toxins derived from bacterial infection can enter the ER lumen and inhibit Glucose-Regulated Protein (GRP)78, the chaperone that inhibits the three initiators of UPR, or can increase anti-chaperone antibodies leading to UPR activation [94]. Furthermore, virus can also alter the UPR activating or inhibiting one of the UPR branches [89]. The UPR is part of the immune response, particularly the IRE1 α branch, in many types of living organisms [92]. In mammals UPR, through IRE1 α -TRAF2-Ikk, activates NF- κ B leading to the proinflammatory TNF- α production [89]. The UPR branch initiated by PERK inhibits general protein translation and can also inhibit the translation of regulators of NF- κ B, like nuclear factor of kappa light polypeptide gene enhancer in B-cells Inhibitor (I κ B) [94]. NF- κ B activation induced by ER stress promotes IL-1 β secretion in various cell types, including macrophages and differentiated adipocytes [95]. However, low ER stress preconditioning has opposite effects attenuating TNF- α -induced NF- κ B activation in endothelial cells [89]. Furthermore, UPR can activate proinflammatory kinases, such as c-Jun N-terminal kinases (JNK), through the IRE1 α -TRAF2-ASK1 pathway [96]. Chaperones, known to decrease ER stress, reduced JNK activation and improved insulin sensitivity in mice [89]. Through PERK-ATF4-ATF3 and IRE1 α -sXBP-1, UPR can also induce the transcription of cytokine genes [94, 97]. For instance, in macrophages, the activation of IRE1 α -sXBP-1 increases the expression of proinflammatory factors, like IL-6 [98]. Moreover, ER stress can not only be due to, but also induce the accumulation of ROS [99]. An excessive accumulation of ROS can have proinflammatory effects, by inducing inflammasome activation [100] and promoting CASP-1-dependent IL-1 β secretion [101]. Furthermore, ER stress can also activate the NLRP3 inflammasome in human macrophages triggering IL-1 β secretion [102]. This positive feedback between infection inducing UPR activation and UPR inducing inflammation can lead to chronic diseases, like diabetes [103].

Insufficient or excessive nutrient supply leads to metabolic stress. A chronic excessive nutrient supply is involved in many metabolic diseases including obesity, insulin resistance

and diabetes. Saturated fatty acids can incorporate in the ER membrane of pancreatic β -cells, and probably in other cell types and other membranes [104, 105], This can lead to reduced sphingomyelin and cholesterol levels, that are needed to form ER membrane lipid rafts, essential to transport vesicles to the Golgi apparatus [106]. This leads to the accumulation of proteins inside the ER and consequently ER stress and the activation of the UPR [106, 107]. On the contrary, unsaturated fatty acids can inhibit ER stress [108]. In macrophages, the increase of cholesterol in ER membranes depletes ER calcium stores leading to UPR activation and consequent activation of caspase-3 and the expression of the UPR-dependent proapoptotic CHOP, culminating in macrophage apoptosis [109]. High levels of circulating glucose activate the UPR, either directly or through the increase in ROS levels [110–112].

Usually, the chronic consumption of excessive lipids and excessive sugars is simultaneous. In fact, the modern diet with high consumption of refined vegetable oils and sugars, highly processed cereals, dairy products and a high ratio of omega-6 to omega-3 polyunsaturated fatty acids contributes to low-grade chronic inflammation [113]. Moreover, high levels of circulating saturated fatty acids and sugars are common in obesity and diabetes, leading to a synergistic effect named glucolipotoxicity [114]. In adipocytes and pancreatic β -cells, UPR activation is a mediator between glucolipotoxicity and inflammation [111]. In obesity, visceral adipocytes release fatty acids and inflammatory factors into the circulation leading to the accumulation of triglycerides in the liver, muscle and pancreas, impairing insulin and glucose homeostasis and contributing to chronic inflammation [115, 116]. On the other hand, weight loss reduces insulin resistance, glucolipotoxicity, adipose tissue inflammation and the risk of diabetes, some times more effective than drug interventions, preserves β -cell function and increases beneficial adiponectin secretion [117].

UPR can induce the activation of autophagy through different pathways [118]. Autophagy is of major importance for the maintenance of cellular fitness through the degradation of unwanted proteins and organelles. It is also activated during nutrient deprivation, where it serves as a source of amino acids, free fatty acids for ATP production and other nutrients. On the other hand, amino acids and insulin inhibit autophagy initiation [119].

There is increasing evidence that activation of autophagy improves insulin resistance [120, 121]. However, insulin resistance can also increase autophagy [122], because insulin is not activating its receptor to the same extent and consequently the activation of the pathway that leads to autophagy inhibition is decreased. In fact, defects in autophagy are associated with diabetes and obesity and can induce ER stress [123]. Moreover, pancreatic β -cells in T2DM patients have increased autophagic vacuoles and autophagosomes associated with cell death [124]. On the other hand, dysfunctional autophagy can induce insulin resistance [123, 125, 126].

Autophagy is also involved in antigenic peptide processing and promotes the development and survival of B and T cells [127, 128], enhancing innate and adaptive immune responses. Defects in autophagic pathways lead to increased inflammation [129] and defects in ER stress induced autophagy are involved in chronic inflammation observed in diabetic patients [130].

Obesity and diabetes also have a large impact on specific populations of immune cells. Macrophage polarization is significantly altered by obesity and diabetes, favoring the M1 pro-inflammatory phenotype [131] that, through IL-6 and TNF- α secretion promotes low-grade chronic inflammation and insulin resistance [132]. This effect is partially due to the role of oxidized phospholipids, that regulate gene expression in adipose tissue macrophages, favoring M1 polarization [131]. Recent data puts microRNA (miR)-30 downregulation in the center of adipose tissue macrophage induced chronic inflammation [132]. Regardless of the driving force behind M1 polarization in obese and diabetic individuals, we know that the process is reversible because, at least in mice, dietary restriction leads to a decrease in macrophage adipose tissue infiltration and a consequent decrease in IL-6, TNF- α and IL-1 β levels [133].

Neutrophils are also recruited to the adipose tissue in obese and diabetic individuals [134], where they differentiate to the pro-inflammatory N1 phenotype and contribute to chronic inflammation [135].

Diabetes and obesity have an enormous impact on T-cell differentiation and function, as recently and thoroughly reviewed [136]. Moreover, since T-cells express the insulin receptor upon stimulation [137] they are sensitive to differences in glucose concentrations, and hyperglycemia alone is able to activate NF- κ B [138], impairing leukocyte activation [139] and migration [140]. We already know that Glucose transporter (Glut1) is selectively essential for CD4⁺ T-cell activation and effector function [141], but little else is known about how differences in glucose concentrations change the cytokine secretion profile of activated T-cells. Nonetheless, an accumulation of effector T-cells and consequent reduction in T-Cell Receptor (TCR) repertoire diversity has already been reported in diabetic patients [7].

Recently, new evidence has even suggested that B cells also play a role in chronic low-grade inflammation. B cells also infiltrate adipose tissues where they work as antigen presenting cells and contribute to insulin resistance and inflammation by secreting Interferon (IFN)- γ , IL-12 and TNF- α , as well as pathogenic antibodies [142]. Moreover, these effects seem to be, at least in part, regulated by leptin [143] and saturated fatty acids [144]. The same effect is also associated with aging [145].

It is clear that obesity and diabetes contribute to low-grade chronic inflammation, with impact on a variety of immune cells and processes. Accumulating evidence starts to suggest that the immunometabolism is itself altered by obesity and diabetes, with a strong impact in the immune response.

III. IMMUNOMETABOLISM

Immune cells switch between different metabolic pathways in response to different stimuli and in different conditions [146]. For example, M1 macrophages are avid glucose consumers and get most of their energy from glycolysis, whereas M2 macrophages prefer a steady state ATP generation program and favor the Tricarboxylic Acid (TCA) cycle and oxidative phosphorylation [147]. Moreover, PPAR-Gamma-Coactivator-1beta (PGC-1 β), known for its central role in the transcriptional control of mitochondrial biogenesis and respiratory

function [148], also decreases macrophage response to free fatty acids [149] and induces M2 polarization [150].

One of the hallmarks of immunometabolism has been the intrinsic relation between glycolytic metabolism and T-cell activation. In fact T-cell activation and differentiation relies so greatly on glycolysis that inhibiting this pathway completely blocks effector T-cell differentiation [151]. Moreover, accumulating evidence suggests that the extent of T-cell clonal expansion is controlled by the proficiency of the glycolytic metabolism [152] and thus glucose and oxygen availability is determinant. The result of this glycolytic burst is the production of lactate (Warburg effect) that regulates both cell migration and effector functions [153]. Despite the extensive glycolytic switch, mitochondrial function is still important for T-cells, both at the level of calcium and ROS signaling and through the production of building blocks important for many anabolic processes that support cell proliferation and migration [154].

Mounting evidence suggests an important role for leptin in T-cell activation [155] and differentiation [156], through the up-regulation of Glut1 and concomitant increase in glucose uptake [155]. In fact, only effector T-cell Glut1 expression seems to be regulated by leptin and no effect was observed in naïve or regulatory T-cells [155]. Moreover, leptin signaling favors pro-inflammatory Th17 T-cell polarization [157] through a Hypoxia-Inducible Factor (HIF)-1 α mediated pathway [156]. This is of particular importance since leptin levels are significantly higher in obese [158] and T2DM patients [159], thus explaining why effector T-cells accumulate in these individuals, contributing to the chronic low-grade inflammation phenotype [160] that is particularly more severe in the adipose tissue [161], where leptin is produced.

Moreover, molecules that mimic the biochemical and functional effects of caloric restriction, such as aspirin [162], 2-Deoxyglucose [163], fisetin [164] and others that have immunomodulatory effects, reduce chronic inflammation [165]. This is of particular interest to the field of diabetes because metformin, one of the most broadly used drugs for glycemic control, is also a caloric restriction mimetic [165] and has the ability to reduce chronic inflammation [166].

All recent evidence points in the direction of a strong and decisive impact of metabolism in T and B-cell priming and expansion and its important role in age and diabetes associated chronic inflammation.

IV. B CELLS AND AGING

Tissues with regenerative capacity are able to continuously produce renewed cells throughout life, a process that is maintained due to the presence of tissue-specific stem cells. As described elsewhere [167, 168], tissues with a regenerative capacity change with aging, but their regenerative capacity is not fully abolished. Thus, and as an example, despite accumulation of senescent characteristics in the aged skin, epidermal stem cells are maintained at normal levels throughout life [169]. Lymphocytes develop from Hematopoietic Stem Cells (HSC) that will posteriorly differentiate into early common

lymphoid progenitors, that will differentiate either into T or B lymphocytes. In parallel, myeloid progenitors will generate myeloid leukocyte populations. Aleatory rearrangement of V(D)J segments in the gene that codes for the variable portion of immunoglobulins occurs during lymphocyte maturation and generates an almost infinite repertoire of antigen recognition on T and B lymphocytes. During adulthood, the size of the lymphocyte compartment is maintained by equal production and loss rates [170]. In adult mice, approximately 10^7 immature B cells are generated daily, however about only 3% of these survive positive and negative selection to form the pool of mature B cells in secondary lymphoid organs [170, 171]. The rate of lymphopoiesis dramatically declines with aging because of cell-intrinsic and extrinsic factors that affect HSC, as well as early and late lymphoid progenitors. Several studies revealed that, with age, lymphoid differentiation diminishes in favor of myeloid differentiation, which affects directly the pool of naïve lymphocytes and clonal diversity, promoting higher frequencies of long-lived memory cells or innate-like lymphocyte populations. It was also proposed that DNA damage may alter lineage potential and responsiveness to trophic signals [172–175]. Importantly, it has been demonstrated that the composition of the stem cell compartment in aging is dominated by myeloid-biased HSCs [176, 177], with down-regulation of genes associated with lymphoid lineage and up-regulation of genes directing myeloid lineage [173, 178].

As a consequence of a reduced lymphopoiesis, the number and proliferative abilities of B-cell progenitors and immature B cells in the Bone-Marrow (BM) declines with age [171, 179]. It is also described that, with age, there is decreased IL-7 production, and impaired V-DJ rearrangement [180, 181]. Several studies show that when BM cells or purified HSCs from old mice were adoptively transferred into irradiated younger (adult) mice, they poorly reconstituted the peripheral B-cell compartment [173, 182–184].

Despite the decline in lymphopoiesis, there are no significant changes in the absolute numbers of peripheral B and T-cells with age [185, 186]. However, the cellular composition of the peripheral compartment is dramatically changed in old age. Perhaps the most significant change is the accumulation of long-lived memory cells and the decline in frequencies of naïve cells. B cells in aged mice have a significantly longer life span than peripheral B cells in younger mice [187]. Indeed, analysis of B-lineage cells in old mice revealed a significant decrease in the number of naïve B-2 cells (which are short-lived and primarily reside in the follicular compartment) and a significant increase in peripheral B cells expressing antigen-experienced long-lived phenotypes, including memory B cells, B-1 cells, and marginal zone B cells [185, 188]. It is also interesting to notice that the onset of type I diabetes is also associated with an increase in the frequencies and total numbers of B-1 cells [189–192].

Until recently, it was thought that lymphocyte aging was an irreversible process. However, studies from Melamed and colleagues showed that this may not be the case, shedding some light into how inflammaging in chronic inflammatory conditions (such as diabetes) could be addressed or clinically ameliorated. The authors showed that the main cause for reduced lymphopoiesis and the consequent loss of clonal diverse naïve B cells are not cell intrinsic defects but, instead, a reduced number of HSCs with lymphocyte lineage potential. Keren et al. showed that aged mice had significantly lower number of HSCs that retained the potential

to differentiate in early lymphoid progenitors; however, these lymphoid HSCs retained the same ability to proliferate and generate lymphocytes. Thus, when these lymphoid HSCs were transferred into irradiated aged recipients they were perfectly able to regenerate the pool of naïve and clonal diverse B cells [193, 194]. Also, the same authors demonstrated that several rounds of peripheral lymphocyte depletion reverse the “aging” state of B cells in secondary lymphoid organs, originating a “young-like” repertoire of B-cells [194].

Thus, altogether, it seems that with aging, the demand for newly generated lymphocytes diminishes because the expansion of the memory cell pool is probably favored. In fact, it is plausible to assume that, with increased age, the number of neo antigens that our body is exposed to diminishes significantly. This, in turn, will favor the maintenance of antigen-experienced memory lymphocytes in detriment of recently-formed naïve B (and T) cells. Also, inflammatory signals or mitogen-induced polyclonal IgM seem to affect directly the pool of lymphocyte precursors in the BM [195, 196], which can also explain why during chronic inflammatory conditions the clonal diversity of T and B-cells reduces dramatically. The ability to rejuvenate the peripheral compartment by depletion of B-cells is supported clinically in patients treated with rituximab (a monoclonal antibody directed towards the surface antigen CD20, that causes B-cell depletion). In these patients, the newly generated B-cells post-treatment, express a young phenotype and a diverse repertoire [197, 198]. However, only replacing the B lineage is not enough to achieve complete restoration of a “young-like” immune response. Age-related defects are also developing in the T lineage and innate cells. Production of T-cells depends on further maturation and selection of progenitor cells in the thymus, which undergoes atrophy with age.

V. T-CELL PRIMING AND EXPANSION

Since Burnet elucidated GOD (generation of diversity) and its central role in the adaptive immune response, immunologists have tried to estimate the size of the TCR repertoire and how it evolves with age. The minimal estimate of the Human naïve TCR repertoire is thought to be of the 10^8 magnitude at birth [199] and linearly declines after thymic involution, reaching a 10^6 magnitude in the 7th decade [200] and steeply declining thereafter [201]. This age-associated repertoire restriction generates holes that lead to impaired anti-pathogen [202] and anti-cancer immunity [203]. Moreover, degenerate T-cell recognition of peptide-Major Histocompatibility Complex (MHC)-I complexes can further exacerbate the physiological importance of these repertoire holes [204].

Various studies have already demonstrated that some infections that cause a strong T-cell stimulation may cause a deleterious effect on TCR repertoire diversity and thus have a huge impact on the immune response to subsequent infections by different pathogens [205]. This effect is mainly due to the competition for resources (such as IL-2) that mediates the survival of naïve cells and limits the total T-cell count [206]. Other studies have demonstrated that regular pathogen encounters significantly reduce the diversity of the TCR repertoire in aged individuals [199].

Moreover, age-associated thymic involution [207] and hematopoietic progenitor cell decline [208] lead to a lower rate of naïve T-cell renewal, further contributing to the reduction in

TCR repertoire diversity. Nevertheless, it has also been demonstrated that there is a fair amount of plasticity in the TCR repertoire, mainly due to cross-reactivity, that compensates for the reduction in TCR repertoire diversity [209], but this effect may be limited.

A reduction in TCR repertoire diversity and a decline in naïve T-cell numbers is also observed in diabetic patients [7], in much younger ages, possibly explaining the higher risk of infection [210] and cancer [211, 212] in these individuals, especially those with longer disease durations and poorer glycemic control.

Besides the reduction in TCR diversity, aging is also associated with a reduction in naïve CD8⁺ T-cell priming efficacy [213], that correlates with poor primary immune responsiveness [214]. This reduction in priming efficacy has already been reported in patients with persistent virus infections [215, 216] and is associated with immune exhaustion.

In diabetic patients, excessive T-cell activation and expansion, driven by high glycemia and high leptin levels, leads to chronic inflammation and severe reduction in TCR diversity that is involved or even responsible for most of the diabetes-associated pathologies, such as chronic diabetic foot ulcerations (Figure 2).

VI. IMPAIRED WOUND HEALING

DFUs are the most debilitating complications of diabetes and are a consequence of uncontrolled infection of foot wounds, often due to various diabetes-associated complications, such as neuropathy, impaired angiogenesis and chronic low-grade inflammation [17] (Figure 3).

Peripheral neuropathy is present in nearly half of non-healing DFU cases [217] and neurological assessment is routinely used in the evaluation of DFU risk. Patients with reduced lower extremity pain sensation are prone to the development of chronic ulcers, because auto-diagnosis is hindered by the inability to detect wounds in the plantar foot regions, until these wounds become dangerously large.

Besides the decreased pain sensation, neuropathy also impairs neuro-immune interactions [218], either through decreased neuropeptide expression [219] or through a reduction in the cholinergic anti-inflammatory effect [220], both capable of modulating inflammation during wound healing. In fact, topical treatment of diabetic wounds with neuropeptides, such as substance P [221], neuropeptide Y [222] or neurotensin [223] reduce inflammation and improve wound healing.

Angiogenesis is also impaired in diabetic foot ulcers [224]. The reduced blood flow restricts macrophage and T-cell chemotaxis [225], impairing the immune response. It also reduces keratinocyte, fibroblast and endothelium progenitor cell migration to the wound [226], impairing tissue regeneration.

The reduced blood flow has a dramatic impact in the healing process, reducing oxygen availability and consequently ATP production [227]. In fact, hyperbaric oxygen therapy

reliefs the need for lactic acid formation and improves wound healing [228], but it does not cure DFU [229]. This is partially because increased mitochondrial activity leads to oxidative stress, which can offset the healing effect in the long-term [230], but also because the lack of energy availability is not the only factor contributing to the wound healing impairment observed in DFU patients [231].

Long-term hyperglycemia leads to chronic inflammation [17] that, in turn, is involved in the etiology of all diabetic microvascular complications [232]. Despite the huge impact of long-term hyperglycemia in the etiology of diabetic complications, several large clinical trials [233, 234] have shown that even though glucose-lowering treatments reduce the risk of cardiovascular disease, the risk of DFU still remains. This indicates that the mechanisms that impair wound healing are multifactorial [235].

ROS are essential for wound repair, however, excessive amounts of ROS have an adverse effect, due to lipid peroxidation, protein modification and DNA damage, all associated with impaired wound repair in chronic, non-healing wounds [236–240]. In addition to ROS-mediated persistent pro-inflammatory cytokine secretion and activation of matrix metalloproteases, excessive ROS can modify and/or degrade extracellular matrix proteins and cause impaired dermal fibroblast and keratinocyte function [241]. ROS are elevated in diabetic wounds [242] and the expression and activity of NADPH Oxidases (NOX), the main source of ROS in many cell types, are increased in hyperglycemic conditions [243]. Moreover, hyperglycemia activates protein kinase C in smooth muscle and endothelial cells which lead to the increased NOX activity [244]. Moreover, diabetic mouse wounds have increased expression and activity of H₂O₂-producing enzyme xanthine oxidase [245].

The mitochondrial electron transport chain is one of the main important sources of ROS in diabetes [244]. Hyperglycemia causes an increase in the production of mitochondrial superoxide [244, 246], promoting the activation of the polyol, protein kinase C, and hexosamine pathways [244, 246] and ultimately depleting antioxidant resources, and promoting further ROS and advanced glycation end products production.

The deleterious effects of ROS on cell function are also related to the reduction in antioxidant defenses. Superoxide Dismutase (SOD), catalase, and glutathione peroxidase activity were reduced in the blood of diabetic patients [247]. In addition, the expression of Nuclear factor erythroid 2-Related Factor 2 (Nrf2), a regulator of antioxidant defense gene expression, is impaired in diabetes [248]. Oxidative stress decreases Nrf2 activity and is associated with reduced catalase, NADPH dehydrogenase Quinone 1 (NQO1), glutathione reductase, and glutathione S-transferase expression [249]. Moreover, high glucose levels decrease nuclear translocation of Nrf2 in dermal fibroblasts and the expression of MnSOD and NQO1 is reduced [250].

Some researchers propose that impaired wound healing in DFU is due to a concomitant excess of pro-inflammatory cytokines, like TNF- α , and a deficit of anti-inflammatory and healing associated cytokines, like IL-10 and TGF- β [251]. This cytokine unbalance explains the excessive M1 macrophage polarization [131] and the accumulation of effector CD8⁺ T-cells in the wound site that, in turn, are responsible for the excessive granzyme secretion that

leads to tissue destruction [252]. Moreover, under diabetic conditions, excessive TNF- α levels prime neutrophils for NETosis [253], even under sterile inflammation [254], also promoting tissue damage. Nonetheless, despite the obvious contribution of the cytokine unbalance to the impaired wound healing, this theory fails to explain why only some DFUs surprisingly become chronic and inflammation is not resolved, when all DFU patients have high pro-inflammatory cytokine levels [252].

Unpublished data from ongoing longitudinal studies by our group suggests that loss of TCR repertoire diversity and accumulation of effector T-cells, together with loss of naïve priming efficacy is the tipping effect that leads to immune exhaustion and the inability to successfully mount *de novo* immune responses that can resolve pathogen infections and heal diabetic wounds.

VII. VACCINATION AS A STRATEGY TO SLOW IMMUNE AGING

The rising prevalence and severity of infectious diseases among the elderly population has a significant negative impact on their quality of life and increases their dependency on healthcare systems. Attempts to improve vaccination efficacy among elderly populations has had only limited success [255], indicating that new innovative approaches are necessary to enhance immune competence and avoid cellular senescence in aging. A major limitation for these attempts is the composition of the different cellular compartments in aging, which can have poor responsiveness [256] and a limited repertoire [257, 258].

Age-related defects are not limited to lymphocytes. Although the number of neutrophils remains unaltered with age, neutrophils from elderly subjects are characterized by a reduced capability to migrate towards a chemotactic signal. Of interest, this reduced chemotactic capacity could also lead to a diminished egress of neutrophils from inflamed tissue, thereby contributing to higher local inflammation, as observed in aged mice after burn-associated lung injury [259, 260]. Moreover, it has also been described that recognition of Pathogen-Associated Molecular Patterns (PAMP) by endogenous Pattern Recognition Receptors (PRR), such as Toll-Like Receptors (TLR), induces increased IL-10 production in the elderly compared with younger adults, increasing their susceptibility to bacterial infections [261–265]. Interestingly, this ability of elder individuals to produce higher levels of IL-10 upon microbial/mitogenic stimulus is shared by neonates and may be due to the increased numbers of B-1 or marginal-zone B lymphocyte sub-populations [261, 266, 267].

Thus, new strategies for developing vaccines would be extremely important to tackle the increased susceptibility of elderly individuals to infections, specifically those caused by fast-growing extracellular bacteria. On the other hand, the stimulus with neo antigens such as those offered by peptide-based epitope targeted vaccines [268–270], would also increase the demand for newly generated B and T cells favoring new lymphopoiesis, which would most likely increase the levels of lymphoid HSCs and slow immune aging. In this regard, vaccination schedule in the elderly (or diabetic) should be rethought, increasing the number of immunizations for each vaccine – 2 to 3 doses, as it is done in the early years of life – in order to potentiate the proliferation of lymphoid HSCs and the output of recently lymphocyte emigrants from BM and thymus. Another issue to be considered is the type of

adjuvant used. For many years, aluminum hydroxide (Alum) has been used with great success. Nevertheless, due to its ability to activate the NALP3 inflammasome and induce a very strong inflammatory response mediated by the IL-1 family of cytokines, it is not the best fit to use in the elderly or in individuals with an already excessive inflammatory condition [271]. Lipid emulsions, analogs of Lipopolysaccharide (LPS) or even agonists of TLR are already being used, inducing very strong immunization responses without the exacerbated peak of inflammation seen with Alum [271–273].

Also, bacterial infections, namely those caused by multi-drug resistant strains of *Staphylococcus aureus*, are known to be responsible for serious complications in diabetic patients [260, 267]. Again, a successful new vaccination approach would be the best-case scenario to avoid complications caused by infection, which would decrease the degree of inflammation and, in turn, would also reduce the tendency of a skewed lymphocyte repertoire.

CONCLUSION

Increasing evidence suggests that immune aging is potentiated by dysmetabolism, resulting in chronic inflammation and loss of immune fitness, with an enormous impact in age-related pathologies [274]. Chronic inflammation can lead to immune exhaustion, as observed in HIV infection [275], autoimmune disorders [276], cancer [277] or simply with old age [278].

Age-related decline in immune fitness is unavoidable because, until our last breath, we are constantly adapting to continuing pathogen infections and, by doing so, accumulating various immune effector cells. As we get better at fighting recurrent infections, we also increase collateral tissue damage and gradually reduce our ability to mount *de novo* immune responses. Due to the gradual loss of homeostatic fitness mechanisms, collateral tissue damage becomes increasingly problematic, creating the perfect habitat for the colonization of new microorganisms.

In diabetic patients, due to chronic dysmetabolism, the magnitude of the immune response is potentiated, leading to accelerated immune aging. Increased energy and metabolite availability are not the sole culprits of diabetes-associated chronic inflammation. Metabolic hormones, especially leptin, also play an important role in immune dysregulation, making them ideal targets for chronic inflammation-associated diabetes complications, such as retinopathy, nephropathy, neuropathy and impaired wound healing.

Impaired wound healing may be a consequence of the accelerated immune aging observed in diabetic patients. Based on this theory and as previously proposed [7], the restriction in TCR repertoire diversity and the accumulation of effector T-cells, both associated with inflammaging, can be used as biomarkers for chronic DFUs.

Thymic involution eventually abolishes the output of naive T-cells in aging, and any attempt to reverse T-cell aging should include the restoration of functional thymic tissue. Several hormones, sex steroids, growth factors, and cytokines have been shown to inhibit or partially restore thymic tissue [279]. The plasticity of the thymic tissue also has been shown in a

recent study where the cortical thymic epithelial cell compartment regenerated-itself after conditional ablation and restored T-cell development [279–281].

Also, immunomodulatory therapies that can decrease non pathogen-specific tissue immunity, as previously reported in lung infection [277], may prove more useful in DFU care, than any currently used treatment.

As a final remark, despite not being the focus of this review, we would like to reflect on the fact that most of the current knowledge considers inflammaging and age- and diabetes-associated decline in the immune response to be gender-independent. This assumption is not based on empirical knowledge but on the lack of data on gender-associated differences in immune responses. Moreover, increasing evidence suggests that there are significant gender differences regarding prevalence and incidence of the most important age-related diseases [282]. Moreover, diabetes-associated complications, such as impaired wound healing, differently affect man and women [283] and male gender is considered one of the risk factors for DFU [284].

ACKNOWLEDGMENTS

The authors would like to acknowledge Doctor Christine Stabell Benn for her critical review of this manuscript and inspiring suggestions.

JM would like to acknowledge funding from HealthyAging2020 CENTRO-01-0145-FEDER-000012-N2323, EL from SFRH/BPD/112883/2015, ACF from SFRH/BPD/101030/2014 and EC from Claude Pepper Older Americans Independence Center 5P30 AG028718 and NIGMS P20GM109096.

REFERENCES

1. Franceschi C, et al., Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci*, 2000 908: p. 244–54. [PubMed: 10911963]
2. Franceschi C, et al., Inflammaging and ‘Garb-aging’. *Trends Endocrinol Metab*, 2017 28(3): p. 199–212. [PubMed: 27789101]
3. Perkisas S and Vandewoude M, Where frailty meets diabetes. *Diabetes Metab Res Rev*, 2016 32 Suppl 1: p. 261–7. [PubMed: 26453435]
4. Fulop T, et al., The Role of Immunosenescence in the Development of Age-Related Diseases. *Rev Invest Clin*, 2016 68(2): p. 84–91. [PubMed: 27103044]
5. Prattichizzo F, et al., “Inflammaging” as a Druggable Target: A Senescence-Associated Secretory Phenotype-Centered View of Type 2 Diabetes. *Oxid Med Cell Longev*, 2016 2016: p. 1810327. [PubMed: 27340505]
6. Davis FM, et al., Dysfunctional Wound Healing in Diabetic Foot Ulcers: New Crossroads. *Curr Diab Rep*, 2018 18(1): p. 2. [PubMed: 29362914]
7. Moura J, et al., Impaired T-cell differentiation in diabetic foot ulceration. *Cell Mol Immunol*, 2017 14(9): p. 758–769. [PubMed: 26996067]
8. Marcos-Pérez D, et al., Frailty in Older Adults Is Associated With Plasma Concentrations of Inflammatory Mediators but Not With Lymphocyte Subpopulations. *Front Immunol*, 2018 9: p. 1056. [PubMed: 29868017]
9. Koch S, et al., Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. *Immun Ageing*, 2008 5: p. 6. [PubMed: 18657274]
10. Broux B, et al., Pathogenic features of CD4+CD28- T cells in immune disorders. *Trends Mol Med*, 2012 18(8): p. 446–53. [PubMed: 22784556]
11. Fulop T, et al., Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? *Front Immunol*, 2017 8: p. 1960. [PubMed: 29375577]

12. Sansoni P, et al., The immune system in extreme longevity. *Exp Gerontol*, 2008 43(2): p. 61–5. [PubMed: 17870272]
13. Cao Dinh H, et al., Association between Immunosenescence Phenotypes and pre-frailty in Older Subjects: Does Cytomegalovirus Play a Role? *J Gerontol A Biol Sci Med Sci*, 2018.
14. Bayard C, et al., Coordinated expansion of both memory T cells and NK cells in response to CMV infection in humans. *Eur J Immunol*, 2016 46(5): p. 1168–79. [PubMed: 26910859]
15. Yoon JW, Ihm SH, and Kim KW, Viruses as a triggering factor of type 1 diabetes and genetic markers related to the susceptibility to the virus-associated diabetes. *Diabetes Res Clin Pract*, 1989 7 Suppl 1: p. S47–58. [PubMed: 2680367]
16. Roberts BW and Cech I, Association of type 2 diabetes mellitus and seroprevalence for cytomegalovirus. *South Med J*, 2005 98(7): p. 686–92. [PubMed: 16108236]
17. Acosta JB, et al., The pro-inflammatory environment in recalcitrant diabetic foot wounds. *Int Wound J*, 2008 5(4): p. 530–9. [PubMed: 19006574]
18. Biagi E, et al., Aging of the human metaorganism: the microbial counterpart. *Age (Dordr)*, 2012 34(1): p. 247–67. [PubMed: 21347607]
19. Nagpal R, et al., Gut microbiome and aging: Physiological and mechanistic insights. *Nutr Healthy Aging*, 2018 4(4): p. 267–285. [PubMed: 29951588]
20. O'Toole PW and Jeffery IB, Gut microbiota and aging. *Science*, 2015 350(6265): p. 1214–5. [PubMed: 26785481]
21. de Groot LC, et al., Lifestyle, nutritional status, health, and mortality in elderly people across Europe: a review of the longitudinal results of the SENECA study. *J Gerontol A Biol Sci Med Sci*, 2004 59(12): p. 1277–84. [PubMed: 15699526]
22. Claesson MJ, et al., Gut microbiota composition correlates with diet and health in the elderly. *Nature*, 2012 488(7410): p. 178–84. [PubMed: 22797518]
23. Miele L, et al., Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. *Curr Cardiol Rep*, 2015 17(12): p. 120. [PubMed: 26497040]
24. Aydin Ö, Nieuwdorp M, and Gerdes V, The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. *Curr Diab Rep*, 2018 18(8): p. 55. [PubMed: 29931613]
25. Moissl-Eichinger C, et al., Human age and skin physiology shape diversity and abundance of Archaea on skin. *Sci Rep*, 2017 7(1): p. 4039. [PubMed: 28642547]
26. Curtiss N, et al., Age, menopausal status and the bladder microbiome. *Eur J Obstet Gynecol Reprod Biol*, 2018 228: p. 126–129. [PubMed: 29936400]
27. Liu F, et al., Characterization of the urinary microbiota of elderly women and the effects of type 2 diabetes and urinary tract infections on the microbiota. *Oncotarget*, 2017 8(59): p. 100678–100690. [PubMed: 29246012]
28. Liu F, et al., Alterations of Urinary Microbiota in Type 2 Diabetes Mellitus with Hypertension and/or Hyperlipidemia. *Front Physiol*, 2017 8: p. 126. [PubMed: 28316574]
29. Gardiner M, et al., A longitudinal study of the diabetic skin and wound microbiome. *PeerJ*, 2017 5: p. e3543. [PubMed: 28740749]
30. Cannizzo ES, et al., Oxidative stress, inflamm-aging and immunosenescence. *J Proteomics*, 2011 74(11): p. 2313–23. [PubMed: 21718814]
31. Alonso-Fernandez P and De la Fuente M, Role of the immune system in aging and longevity. *Curr Aging Sci*, 2011 4(2): p. 78–100. [PubMed: 21235494]
32. Martin-Fernandez B and Gredilla R, Mitochondria and oxidative stress in heart aging. *Age (Dordr)*, 2016 38(4): p. 225–238. [PubMed: 27449187]
33. Kong Y, Trabucco SE, and Zhang H, Oxidative stress, mitochondrial dysfunction and the mitochondria theory of aging. *Interdiscip Top Gerontol*, 2014 39: p. 86–107. [PubMed: 24862016]
34. Lenaz G, et al., Role of mitochondria in oxidative stress and aging. *Ann N Y Acad Sci*, 2002 959: p. 199–213. [PubMed: 11976197]
35. Babizhayev MA and Yegorov YE, Reactive Oxygen Species and the Aging Eye: Specific Role of Metabolically Active Mitochondria in Maintaining Lens Function and in the Initiation of the Oxidation-Induced Maturity Onset Cataract--A Novel Platform of Mitochondria-Targeted

- Antioxidants With Broad Therapeutic Potential for Redox Regulation and Detoxification of Oxidants in Eye Diseases. *Am J Ther*, 2016 23(1): p. e98–117. [PubMed: 21048433]
36. Ma Q, Advances in mechanisms of anti-oxidation. *Discov Med*, 2014 17(93): p. 121–30. [PubMed: 24641954]
 37. De la Fuente M and Miquel J, An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflamm-aging. *Curr Pharm Des*, 2009 15(26): p. 3003–26. [PubMed: 19754376]
 38. Calabrese V, et al., Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. *Mol Aspects Med*, 2011 32(4–6): p. 279–304. [PubMed: 22020114]
 39. Gems D and Partridge L, Stress-response hormesis and aging: “that which does not kill us makes us stronger”. *Cell Metab*, 2008 7(3): p. 200–3. [PubMed: 18316025]
 40. Rosso A, et al., p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. *J Biol Chem*, 2006 281(7): p. 4339–47. [PubMed: 16339764]
 41. Yuan Q, et al., Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine. *Biochem Biophys Res Commun*, 2015 458(4): p. 869–76. [PubMed: 25701782]
 42. Brodsky SV, et al., Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. *Circ Res*, 2004 94(3): p. 377–84. [PubMed: 14670841]
 43. Kilarkaje N and Al-Bader MM, Diabetes-induced oxidative DNA damage alters p53-p21CIP1/Waf1 signaling in the rat testis. *Reprod Sci*, 2015 22(1): p. 102–12. [PubMed: 24828139]
 44. Bitar MS, Abdel-Halim SM, and Al-Mulla F, Caveolin-1/PTRF upregulation constitutes a mechanism for mediating p53-induced cellular senescence: implications for evidence-based therapy of delayed wound healing in diabetes. *Am J Physiol Endocrinol Metab*, 2013 305(8): p. E951–63. [PubMed: 23941874]
 45. Ceriello A, et al., Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. *Diabetes*, 2012 61(11): p. 2993–7. [PubMed: 22891214]
 46. Ceriello A and Testa R, Antioxidant anti-inflammatory treatment in type 2 diabetes. *Diabetes Care*, 2009 32 Suppl 2: p. S232–6. [PubMed: 19875557]
 47. Hyun DH, et al., Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. *Proc Natl Acad Sci U S A*, 2006 103(52): p. 19908–12. [PubMed: 17167053]
 48. Cai W, et al., Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. *Am J Pathol*, 2008 173(2): p. 327–36. [PubMed: 18599606]
 49. Chung KW, et al., Recent advances in calorie restriction research on aging. *Exp Gerontol*, 2013 48(10): p. 1049–53. [PubMed: 23201549]
 50. Maiese K, New Insights for Oxidative Stress and Diabetes Mellitus. *Oxid Med Cell Longev*, 2015 2015: p. 875961. [PubMed: 26064426]
 51. Ding S, et al., Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signaling in high-fat diet-fed mice. *PeerJ*, 2018 6: p. e5173. [PubMed: 29967759]
 52. Jimenez-Gomez Y, et al., Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. *Cell Metab*, 2013 18(4): p. 533–45. [PubMed: 24093677]
 53. Mattison JA, et al., Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. *Cell Metab*, 2014 20(1): p. 183–90. [PubMed: 24882067]
 54. Salvioli S, et al., Immune system, cell senescence, aging and longevity--inflamm-aging reappraised. *Curr Pharm Des*, 2013 19(9): p. 1675–9. [PubMed: 23589904]
 55. Green DR, Oguin TH, and Martinez J, The clearance of dying cells: table for two. *Cell Death Differ*, 2016 23(6): p. 915–26. [PubMed: 26990661]
 56. Zitvogel L, Kepp O, and Kroemer G, Decoding cell death signals in inflammation and immunity. *Cell*, 2010 140(6): p. 798–804. [PubMed: 20303871]

57. Medina CB and Ravichandran KS, Do not let death do us part: 'find-me' signals in communication between dying cells and the phagocytes. *Cell Death Differ*, 2016 23(6): p. 979–89. [PubMed: 26891690]
58. Kaushik S and Cuervo AM, Proteostasis and aging. *Nat Med*, 2015 21(12): p. 1406–1415. [PubMed: 26646497]
59. Lopez-Otin C, et al., The hallmarks of aging. *Cell*, 2013 153(6): p. 1194–1217. [PubMed: 23746838]
60. Labbadia J and Morimoto RI, The biology of proteostasis in aging and disease. *Annu Rev Biochem*, 2015 84: p. 435–464. [PubMed: 25784053]
61. Del Roso A, et al., Ageing-related changes in the in vivo function of rat liver macroautophagy and proteolysis. *Exp Gerontol*, 2003 38(5): p. 519–527. [PubMed: 12742529]
62. Ovadya Y and Krizhanovsky V, Senescent cells: SASPected drivers of age-related pathologies. *Biogerontology*, 2014 15(6): p. 627–642. [PubMed: 25217383]
63. Chondrogianni N, et al., Fibroblast cultures from healthy centenarians have an active proteasome. *Exp Gerontol*, 2000 35(6–7): p. 721–728. [PubMed: 11053662]
64. He LQ, Lu JH, and Yue ZY, Autophagy in ageing and ageing-associated diseases. *Acta Pharmacol Sin*, 2013 34(5): p. 605–611. [PubMed: 23416930]
65. Meijer AJ and Codogno P, Autophagy: regulation and role in disease. *Crit Rev Clin Lab Sci*, 2009 46(4): p. 210–240. [PubMed: 19552522]
66. Koga H, Kaushik S, and Cuervo AM, Protein homeostasis and aging: The importance of exquisite quality control. *Ageing Res Rev*, 2011 10(2): p. 205–215. [PubMed: 20152936]
67. Fujikake N, Shin M, and Shimizu S, Association Between Autophagy and Neurodegenerative Diseases. *Front Neurosci*, 2018 12: p. 255. [PubMed: 29872373]
68. Fonseca ACRG, et al., Loss of proteostasis induced by amyloid beta peptide in brain endothelial cells. *BBA - Molecular Cell Research*, 2014 1843(6): p. 1150–1161. [PubMed: 24589617]
69. Walker C and El-Khamisy SF, Perturbed autophagy and DNA repair converge to promote neurodegeneration in amyotrophic lateral sclerosis and dementia. *Brain*, 2018 141(5): p. 1247–1262. [PubMed: 29584802]
70. Li H, et al., Defective autophagy in osteoblasts induces endoplasmic reticulum stress and causes remarkable bone loss. *Autophagy*, 2018.
71. Remondelli P and Renna M, The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance. *Front Mol Neurosci*, 2017 10: p. 187. [PubMed: 28670265]
72. Martinez-Lopez N, Athonvarangkul D, and Singh R, Autophagy and aging. *Adv Exp Med Biol*, 2015 847: p. 73–87. [PubMed: 25916586]
73. Fonseca ACRG, et al., The role of proteotoxic stress in vascular dysfunction in the pathogenesis of Alzheimer's disease. *Endoplasmic Reticulum Stress in Diseases*, 2015 2: p. 67–81.
74. Holmes C, Review: systemic inflammation and Alzheimer's disease. *Neuropathol Appl Neurobiol*, 2013 39(1): p. 51–68. [PubMed: 23046210]
75. Krstic D and Knuesel I, Deciphering the mechanism underlying late-onset Alzheimer disease. *Nat Rev Neurol*, 2013 9(1): p. 25–34. [PubMed: 23183882]
76. Dzamko N, Geczy CL, and Halliday GM, Inflammation is genetically implicated in Parkinson's disease. *Neuroscience*, 2015 302: p. 89–102. [PubMed: 25450953]
77. Bultink IE and Lems WF, Osteoarthritis and osteoporosis: what is the overlap? *Curr Rheumatol Rep*, 2013 15(5): p. 328. [PubMed: 23508809]
78. Hotamisligil GS, Inflammation and metabolic disorders. *Nature*, 2006 444(7121): p. 860–7. [PubMed: 17167474]
79. Snodgrass RG, et al., Inflammasome-mediated secretion of IL-1 β in human monocytes through TLR2 activation; modulation by dietary fatty acids. *J Immunol*, 2013 191(8): p. 4337–47. [PubMed: 24043885]
80. Jakobsdottir G, et al., High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. *PLoS One*, 2013 8(11): p. e80476. [PubMed: 24236183]

81. Kohlgruber A and Lynch L, Adipose tissue inflammation in the pathogenesis of type 2 diabetes. *Curr Diab Rep*, 2015 15(11): p. 92. [PubMed: 26374569]
82. Goldberg EL and Dixit VD, Drivers of age-related inflammation and strategies for healthspan extension. *Immunol Rev*, 2015 265(1): p. 63–74. [PubMed: 25879284]
83. Strissel KJ, et al., Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes*, 2007 56(12): p. 2910–8. [PubMed: 17848624]
84. Ruegsegger C and Saxena S, Proteostasis impairment in ALS. *Brain Res*, 2016 1648(Pt B): p. 571–579. [PubMed: 27033833]
85. Yilmaz E, Endoplasmic Reticulum Stress and Obesity. *Adv Exp Med Biol*, 2017 960: p. 261–276. [PubMed: 28585203]
86. Hampton RY, ER-associated degradation in protein quality control and cellular regulation. *Curr Opin Cell Biol*, 2002 14(4): p. 476–482. [PubMed: 12383799]
87. Kruse KB, Brodsky JL, and McCracken AA, Autophagy: an ER protein quality control process. *Autophagy*, 2006 2(2): p. 135–137. [PubMed: 16874086]
88. Jäger R, et al., The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress. *Biol Cell*, 2012 104(5): p. 259–270. [PubMed: 22268789]
89. Bettigole SE and Glimcher LH, Endoplasmic reticulum stress in immunity. *Annu Rev Immunol*, 2015 33: p. 107–138. [PubMed: 25493331]
90. Fu S, Watkins SM, and Hotamisligil GS, The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. *Cell Metab*, 2012 15(5): p. 623–634. [PubMed: 22560215]
91. Mukherjee K, Bhattacharyya S, and Peralta-Yahya P, GPCR-Based Chemical Biosensors for Medium-Chain Fatty Acids. *ACS Synth Biol*, 2015 4(12): p. 1261–9. [PubMed: 25992593]
92. Janssens S, Pulendran B, and Lambrecht BN, Emerging functions of the unfolded protein response in immunity. *Nat Immunol*, 2014 15(10): p. 910–919. [PubMed: 25232821]
93. Berda-Haddad Y, et al., Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. *Proc Natl Acad Sci U S A*, 2011 108(51): p. 20684–20689. [PubMed: 22143786]
94. Reverendo M, et al., At the crossway of ER-stress and proinflammatory responses. *Febs J*, 2018.
95. Kim S, et al., Endoplasmic reticulum stress is sufficient for the induction of IL-1beta production via activation of the NF-kappaB and inflammasome pathways. *Innate Immun*, 2014 20(8): p. 799–815. [PubMed: 24217221]
96. Arshad M, et al., RNF13, a RING finger protein, mediates endoplasmic reticulum stress-induced apoptosis through the inositol-requiring enzyme (IRE1alpha)/c-Jun NH2-terminal kinase pathway. *J Biol Chem*, 2013 288(12): p. 8726–36. [PubMed: 23378536]
97. Kim S, et al., Endoplasmic reticulum stress is sufficient for the induction of IL-1β production via activation of the NF-κB and inflammasome pathways. *Innate Immun*, 2014 20(8): p. 799–815. [PubMed: 24217221]
98. Martinon F, et al., TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. *Nat Immunol*, 2010 11(5): p. 411–418. [PubMed: 20351694]
99. Fonseca ACRG, Cardoso SM, and Pereira C, Calcium and redox homeostasis in Alzheimer's disease: a focus on the endoplasmic reticulum. *Therapeutic Targets for Neurological Diseases*, 2014 1: p. e428.
100. Mittal M, et al., Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal*, 2014 20(7): p. 1126–1167. [PubMed: 23991888]
101. Zhou R, et al., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. *Nat Immunol*, 2010 11(2): p. 136–140. [PubMed: 20023662]
102. Menu P, et al., ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. *Cell Death Dis*, 2012 3: p. e261. [PubMed: 22278288]
103. Hotamisligil GS, Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell*, 2010 140(6): p. 900–917. [PubMed: 20303879]
104. Megha and London E, Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. *J Biol Chem*, 2004 279(11): p. 9997–10004. [PubMed: 14699154]

105. Peng G, et al., Oleate blocks palmitate-induced abnormal lipid distribution, endoplasmic reticulum expansion and stress, and insulin resistance in skeletal muscle. *Endocrinology*, 2011 152(6): p. 2206–2218. [PubMed: 21505048]
106. Boslem E, et al., Alteration of endoplasmic reticulum lipid rafts contributes to lipotoxicity in pancreatic beta-cells. *J Biol Chem*, 2013 288(37): p. 26569–26582. [PubMed: 23897822]
107. Preston AM, et al., Reduced endoplasmic reticulum (ER)-to-Golgi protein trafficking contributes to ER stress in lipotoxic mouse beta cells by promoting protein overload. *Diabetologia*, 2009 52(11): p. 2369–2373. [PubMed: 19727664]
108. Katsouliris E, et al., alpha-Linolenic acid protects renal cells against palmitic acid lipotoxicity via inhibition of endoplasmic reticulum stress. *Eur J Pharmacol*, 2009 623(1–3): p. 107–112. [PubMed: 19765573]
109. Feng B, et al., The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. *Nat Cell Biol*, 2003 5(9): p. 781–792. [PubMed: 12907943]
110. Mooradian AD and Haas MJ, Glucose-induced endoplasmic reticulum stress is independent of oxidative stress: A mechanistic explanation for the failure of antioxidant therapy in diabetes. *Free Radic Biol Med*, 2011 50(9): p. 1140–1143. [PubMed: 21320588]
111. Ghemrawi R, Battaglia-Hsu SF, and Arnold C, Endoplasmic Reticulum Stress in Metabolic Disorders. *Cells*, 2018 7(6).
112. Bensellam M, Laybutt DR, and Jonas JC, The molecular mechanisms of pancreatic beta-cell glucotoxicity: recent findings and future research directions. *Mol Cell Endocrinol*, 2012 364(1–2): p. 1–27. [PubMed: 22885162]
113. Ilich JZ, et al., Low-grade chronic inflammation perpetuated by modern diet as a promoter of obesity and osteoporosis. *Arh Hig Rada Toksikol*, 2014 65(2): p. 139–148. [PubMed: 24945416]
114. Karunakaran U, et al., Guards and culprits in the endoplasmic reticulum: glucolipotoxicity and beta-cell failure in type II diabetes. *Exp Diabetes Res*, 2012 2012: p. 639762. [PubMed: 21977023]
115. Booth A, et al., Adipose tissue: an endocrine organ playing a role in metabolic regulation. *Horm Mol Biol Clin Investig*, 2016 26(1): p. 25–42.
116. Morigny P, et al., Adipocyte lipolysis and insulin resistance. *Biochimie*, 2016 125: p. 259–266. [PubMed: 26542285]
117. Mazza AD, Pratley RE, and Smith SR, Beta-cell preservation...Is weight loss the answer? *Rev Diabet Stud*, 2011 8(4): p. 446–453. [PubMed: 22580726]
118. Deegan S, et al., Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress. *Cell Mol Life Sci*, 2013 70(14): p. 2425–2441. [PubMed: 23052213]
119. Lavallard VJ, et al., Autophagy, signaling and obesity. *Pharmacol Res*, 2012 66(6): p. 513–525. [PubMed: 22982482]
120. Zhou W and Ye S, Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy. *Cell Biol Int*, 2018.
121. Liu Y, et al., Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high-fat diet feeding in mice. *Diabetes*, 2015 64(1): p. 36–48. [PubMed: 25071026]
122. Ebato C, et al., Autophagy is important in islet homeostasis and compensatory increase of beta cell mass in response to high-fat diet. *Cell Metab*, 2008 8(4): p. 325–332. [PubMed: 18840363]
123. Yang L, et al., Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. *Cell Metab*, 2010 11(6): p. 467–478. [PubMed: 20519119]
124. Masini M, et al., Autophagy in human type 2 diabetes pancreatic beta cells. *Diabetologia*, 2009 52(6): p. 1083–1086. [PubMed: 19367387]
125. Jung HS, et al., Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. *Cell Metab*, 2008 8(4): p. 318–324. [PubMed: 18840362]
126. Chang YC, et al., Resveratrol protects muscle cells against palmitate-induced cellular senescence and insulin resistance through ameliorating autophagic flux. *J Food Drug Anal*, 2018 26(3): p. 1066–1074. [PubMed: 29976399]

127. Munz C, Enhancing immunity through autophagy. *Annu Rev Immunol*, 2009 27: p. 423–449. [PubMed: 19105657]
128. Levine B and Deretic V, Unveiling the roles of autophagy in innate and adaptive immunity. *Nat Rev Immunol*, 2007 7(10): p. 767–777. [PubMed: 17767194]
129. Lapaquette P, et al., Cellular and Molecular Connections between Autophagy and Inflammation. *Mediators Inflamm*, 2015 2015: p. 398483. [PubMed: 26221063]
130. Wang Y, et al., Autophagy regulates inflammation following oxidative injury in diabetes. *Autophagy*, 2013 9(3): p. 272–277. [PubMed: 23343748]
131. Kraakman MJ, et al., Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? *Front Immunol*, 2014 5: p. 470. [PubMed: 25309549]
132. Miranda K, et al., MicroRNA-30 modulates metabolic inflammation by regulating Notch signaling in adipose tissue macrophages. *Int J Obes (Lond)*, 2018.
133. Ishaq A, et al., Dietary Restriction Ameliorates Age-Related Increase in DNA Damage, Senescence and Inflammation in Mouse Adipose Tissue. *J Nutr Health Aging*, 2018 22(4): p. 555–561. [PubMed: 29582897]
134. Elgazar-Carmon V, et al., Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. *J Lipid Res*, 2008 49(9): p. 1894–903. [PubMed: 18503031]
135. Nijhuis J, et al., Neutrophil activation in morbid obesity, chronic activation of acute inflammation. *Obesity (Silver Spring)*, 2009 17(11): p. 2014–8. [PubMed: 19390527]
136. Touch S, Clément K, and André S, T Cell Populations and Functions Are Altered in Human Obesity and Type 2 Diabetes. *Curr Diab Rep*, 2017 17(9): p. 81. [PubMed: 28779366]
137. Maciolek JA, Pasternak JA, and Wilson HL, Metabolism of activated T lymphocytes. *Curr Opin Immunol*, 2014 27: p. 60–74. [PubMed: 24556090]
138. Dickinson S, et al., High-glycemic index carbohydrate increases nuclear factor-kappaB activation in mononuclear cells of young, lean healthy subjects. *Am J Clin Nutr*, 2008 87(5): p. 1188–93. [PubMed: 18469238]
139. Stegenga ME, et al., Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. *Diabet Med*, 2008 25(2): p. 157–64. [PubMed: 18290856]
140. Bogdanski P, et al., Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. *Int J Clin Pharmacol Ther*, 2007 45(10): p. 563–7. [PubMed: 17966842]
141. Macintyre AN, et al., The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. *Cell Metab*, 2014 20(1): p. 61–72. [PubMed: 24930970]
142. Winer DA, et al., B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. *Cell Mol Life Sci*, 2014 71(6): p. 1033–43. [PubMed: 24127133]
143. Agrawal S, et al., Leptin activates human B cells to secrete TNF- α , IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. *J Clin Immunol*, 2011 31(3): p. 472–8. [PubMed: 21243519]
144. Shi H, et al., TLR4 links innate immunity and fatty acid-induced insulin resistance. *J Clin Invest*, 2006 116(11): p. 3015–25. [PubMed: 17053832]
145. Frasca D and Blomberg BB, Adipose Tissue Inflammation Induces B Cell Inflammation and Decreases B Cell Function in Aging. *Front Immunol*, 2017 8: p. 1003. [PubMed: 28894445]
146. O'Neill LA, Kishton RJ, and Rathmell J, A guide to immunometabolism for immunologists. *Nat Rev Immunol*, 2016 16(9): p. 553–65. [PubMed: 27396447]
147. Zhu L, et al., Cellular metabolism and macrophage functional polarization. *Int Rev Immunol*, 2015 34(1): p. 82–100. [PubMed: 25340307]
148. Scarpulla RC, Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim Biophys Acta*, 2011 1813(7): p. 1269–78. [PubMed: 20933024]
149. Chen H, et al., PGC-1 β suppresses saturated fatty acid-induced macrophage inflammation by inhibiting TAK1 activation. *IUBMB Life*, 2016 68(2): p. 145–55. [PubMed: 26748475]
150. Vats D, et al., Oxidative metabolism and PGC-1 β attenuate macrophage-mediated inflammation. *Cell Metab*, 2006 4(1): p. 13–24. [PubMed: 16814729]

151. Patsoukis N, et al., PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. *Nat Commun*, 2015 6: p. 6692. [PubMed: 25809635]
152. Argus JP and Bensinger SJ, Immunology. Fueling function over expansion in T cells. *Science*, 2013 341(6141): p. 37–8. [PubMed: 23828930]
153. Haas R, et al., Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. *PLoS Biol*, 2015 13(7): p. e1002202. [PubMed: 26181372]
154. Desdín-Micó G, Soto-Herederó G, and Mittelbrunn M, Mitochondrial activity in T cells. *Mitochondrion*, 2018 41: p. 51–57. [PubMed: 29032101]
155. Saucillo DC, et al., Leptin metabolically licenses T cells for activation to link nutrition and immunity. *J Immunol*, 2014 192(1): p. 136–44. [PubMed: 24273001]
156. Gerriets VA, et al., Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. *Eur J Immunol*, 2016 46(8): p. 1970–83. [PubMed: 27222115]
157. Reis BS, et al., Leptin receptor signaling in T cells is required for Th17 differentiation. *J Immunol*, 2015 194(11): p. 5253–60. [PubMed: 25917102]
158. Lee JH, Reed DR, and Price RA, Leptin resistance is associated with extreme obesity and aggregates in families. *Int J Obes Relat Metab Disord*, 2001 25(10): p. 1471–3. [PubMed: 11673768]
159. Fischer S, et al., Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. *Acta Diabetol*, 2002 39(3): p. 105–10. [PubMed: 12357293]
160. Alwarawrah Y, Kiernan K, and MacIver NJ, Changes in Nutritional Status Impact Immune Cell Metabolism and Function. *Front Immunol*, 2018 9: p. 1055. [PubMed: 29868016]
161. Bharath LP, Ip BC, and Nikolajczyk BS, Adaptive Immunity and Metabolic Health: Harmony Becomes Dissonant in Obesity and Aging. *Compr Physiol*, 2017 7(4): p. 1307–1337. [PubMed: 28915326]
162. Pietrocola F, et al., Aspirin-another caloric-restriction mimetic. *Autophagy*, 2018.
163. Hu K, et al., Caloric Restriction Mimetic 2-Deoxyglucose Alleviated Inflammatory Lung Injury. *Front Immunol*, 2018 9: p. 426. [PubMed: 29552018]
164. Singh S, et al., Fisetin as a caloric restriction mimetic protects rat brain against aging induced oxidative stress, apoptosis and neurodegeneration. *Life Sci*, 2018 193: p. 171–179. [PubMed: 29122553]
165. González O, et al., Caloric restriction and chronic inflammatory diseases. *Oral Dis*, 2012 18(1): p. 16–31. [PubMed: 21749581]
166. Saisho Y, Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. *Endocr Metab Immune Disord Drug Targets*, 2015 15(3): p. 196–205. [PubMed: 25772174]
167. Choi J, et al., Intestinal crypts recover rapidly from focal damage with coordinated motion of stem cells that is impaired by aging. *Sci Rep*, 2018 8(1): p. 10989. [PubMed: 30030455]
168. Martin K, Kirkwood TB, and Potten CS, Age changes in stem cells of murine small intestinal crypts. *Exp Cell Res*, 1998 241(2): p. 316–23. [PubMed: 9637773]
169. Farage MA, et al., Characteristics of the Aging Skin. *Adv Wound Care (New Rochelle)*, 2013 2(1): p. 5–10. [PubMed: 24527317]
170. Miller JP and Cancro MP, B cells and aging: balancing the homeostatic equation. *Exp Gerontol*, 2007 42(5): p. 396–9. [PubMed: 17344004]
171. Shahaf G, Johnson K, and Mehr R, B cell development in aging mice: lessons from mathematical modeling. *Int Immunol*, 2006 18(1): p. 31–9. [PubMed: 16291657]
172. Chambers SM, et al., Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. *PLoS Biol*, 2007 5(8): p. e201. [PubMed: 17676974]
173. Rossi DJ, et al., Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc Natl Acad Sci U S A*, 2005 102(26): p. 9194–9. [PubMed: 15967997]
174. Rossi DJ, et al., Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature*, 2007 447(7145): p. 725–9. [PubMed: 17554309]

175. Inomata K, et al., Genotoxic stress abrogates renewal of melanocyte stem cells by triggering their differentiation. *Cell*, 2009 137(6): p. 1088–99. [PubMed: 19524511]
176. Morita Y, Ema H, and Nakauchi H, Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. *J Exp Med*, 2010 207(6): p. 1173–82. [PubMed: 20421392]
177. Beerman I, et al., Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. *Proc Natl Acad Sci U S A*, 2010 107(12): p. 5465–70. [PubMed: 20304793]
178. Lescale C, et al., Reduced EBF expression underlies loss of B-cell potential of hematopoietic progenitors with age. *Aging Cell*, 2010 9(3): p. 410–9. [PubMed: 20331442]
179. Miller JP and Allman D, The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. *J Immunol*, 2003 171(5): p. 2326–30. [PubMed: 12928378]
180. Tsuboi I, et al., Senescent B lymphopoiesis is balanced in suppressive homeostasis: decrease in interleukin-7 and transforming growth factor-beta levels in stromal cells of senescence-accelerated mice. *Exp Biol Med (Maywood)*, 2004 229(6): p. 494–502. [PubMed: 15169968]
181. Szabo P, et al., Impaired rearrangement of IgH V to DJ segments in bone marrow Pro-B cells from old mice. *Cell Immunol*, 2003 222(1): p. 78–87. [PubMed: 12798310]
182. Guerretaz LM, Johnson SA, and Cambier JC, Acquired hematopoietic stem cell defects determine B-cell repertoire changes associated with aging. *Proc Natl Acad Sci U S A*, 2008 105(33): p. 11898–902. [PubMed: 18697924]
183. Koehne G, et al., Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant*, 1997 19(2): p. 149–56. [PubMed: 9116612]
184. Morrison SJ, et al., The aging of hematopoietic stem cells. *Nat Med*, 1996 2(9): p. 1011–6. [PubMed: 8782459]
185. Johnson SA, Rozzo SJ, and Cambier JC, Aging-dependent exclusion of antigen-inexperienced cells from the peripheral B cell repertoire. *J Immunol*, 2002 168(10): p. 5014–23. [PubMed: 11994453]
186. Mitchell WA, Lang PO, and Aspinall R, Tracing thymic output in older individuals. *Clin Exp Immunol*, 2010 161(3): p. 497–503. [PubMed: 20646007]
187. Kline GH, Hayden TA, and Klinman NR, B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation. *J Immunol*, 1999 162(6): p. 3342–9. [PubMed: 10092788]
188. Siegrist CA and Aspinall R, B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol*, 2009 9(3): p. 185–94. [PubMed: 19240757]
189. Munoz A, et al., Increased CD5-positive B lymphocytes in type I diabetes. *Clin Exp Immunol*, 1991 83(2): p. 304–8. [PubMed: 1704297]
190. De Filippo G, et al., Increased CD5+CD19+ B lymphocytes at the onset of type 1 diabetes in children. *Acta Diabetol*, 1997 34(4): p. 271–4. [PubMed: 9451471]
191. Gyarmati J, et al., Fetal type lymphocytes in insulin dependent diabetes mellitus. *Autoimmunity*, 1999 30(2): p. 63–9. [PubMed: 10435718]
192. Kadziela K, et al., Changes in lymphocyte subsets in children with newly diagnosed type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*, 2003 16(2): p. 185–91. [PubMed: 12713255]
193. Melamed D and Scott DW, Aging and neoteny in the B lineage. *Blood*, 2012 120(20): p. 4143–9. [PubMed: 22936664]
194. Keren Z, et al., B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. *Blood*, 2011 117(11): p. 3104–12. [PubMed: 21228330]
195. Pinti M, et al., Aging of the immune system: Focus on inflammation and vaccination. *Eur J Immunol*, 2016 46(10): p. 2286–2301. [PubMed: 27595500]
196. Reina-San-Martin B, Cosson A, and Minoprio P, Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents. *Parasitol Today*, 2000 16(2): p. 62–7. [PubMed: 10652489]
197. Edwards JC and Cambridge G, B-cell targeting in rheumatoid arthritis and other autoimmune diseases. *Nat Rev Immunol*, 2006 6(5): p. 394–403. [PubMed: 16622478]

198. Rouziere AS, et al., Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. *Arthritis Res Ther*, 2005 7(4): p. R714–24. [PubMed: 15987473]
199. Qi Q, et al., Diversity and clonal selection in the human T-cell repertoire. *Proc Natl Acad Sci U S A*, 2014 111(36): p. 13139–44. [PubMed: 25157137]
200. Britanova OV, et al., Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. *J Immunol*, 2014 192(6): p. 2689–98. [PubMed: 24510963]
201. Goronzy JJ, Lee WW, and Weyand CM, Aging and T-cell diversity. *Exp Gerontol*, 2007 42(5): p. 400–6. [PubMed: 17218073]
202. Yager EJ, et al., Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. *J Exp Med*, 2008 205(3): p. 711–23. [PubMed: 18332179]
203. Pawelec G, Does patient age influence anti-cancer immunity? *Semin Immunopathol*, 2018.
204. Calis JJ, de Boer RJ, and Ke mir C, Degenerate T-cell recognition of peptides on MHC molecules creates large holes in the T-cell repertoire. *PLoS Comput Biol*, 2012 8(3): p. e1002412. [PubMed: 22396638]
205. Brunner S, et al., Persistent viral infections and immune aging. *Ageing Res Rev*, 2011 10(3): p. 362–9. [PubMed: 20727987]
206. Stockinger B, Barthlott T, and Kassiotis G, The concept of space and competition in immune regulation. *Immunology*, 2004 111(3): p. 241–7. [PubMed: 15009422]
207. Rezzani R, et al., Thymus and aging: morphological, radiological, and functional overview. *Age (Dordr)*, 2014 36(1): p. 313–51. [PubMed: 23877171]
208. Fali T, et al., Elderly human hematopoietic progenitor cells express cellular senescence markers and are more susceptible to pyroptosis. *JCI Insight*, 2018 3(13).
209. Armstrong KM, Piepenbrink KH, and Baker BM, Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes. *Biochem J*, 2008 415(2): p. 183–96. [PubMed: 18800968]
210. Casqueiro J and Alves C, Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian J Endocrinol Metab*, 2012 16 Suppl 1: p. S27–36. [PubMed: 22701840]
211. Ballotari P, et al., Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. *BMC Cancer*, 2017 17(1): p. 703. [PubMed: 29070034]
212. He X, Shi L, and Wu J, Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China. *Curr Med Res Opin*, 2018 34(6): p. 1089–1098. [PubMed: 29278016]
213. Briceño O, et al., Reduced naïve CD8(+) T-cell priming efficacy in elderly adults. *Aging Cell*, 2016 15(1): p. 14–21. [PubMed: 26472076]
214. Kline KA and Bowdish DM, Infection in an aging population. *Curr Opin Microbiol*, 2016 29: p. 63–7. [PubMed: 26673958]
215. Larsen M, et al., Exhausted cytotoxic control of Epstein-Barr virus in human lupus. *PLoS Pathog*, 2011 7(10): p. e1002328. [PubMed: 22028659]
216. Appay V and Sauce D, Assessing immune aging in HIV-infected patients. *Virulence*, 2017 8(5): p. 529–538. [PubMed: 27310730]
217. Volmer-Thole M and Lobmann R, Neuropathy and Diabetic Foot Syndrome. *Int J Mol Sci*, 2016 17(6).
218. Chavan SS, Ma P, and Chiu IM, Neuro-immune interactions in inflammation and host defense: Implications for transplantation. *Am J Transplant*, 2018 18(3): p. 556–563. [PubMed: 28941325]
219. da Silva L, Carvalho E, and Cruz MT, Role of neuropeptides in skin inflammation and its involvement in diabetic wound healing. *Expert Opin Biol Ther*, 2010 10(10): p. 1427–39. [PubMed: 20738210]
220. Curtis BJ and Radek KA, Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: new perspectives in epidermal immunity and disease. *J Invest Dermatol*, 2012 132(1): p. 28–42. [PubMed: 21918536]
221. Leal EC, et al., Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. *Am J Pathol*, 2015 185(6): p. 1638–48. [PubMed: 25871534]

222. Pradhan Nabzdyk L, et al., Expression of neuropeptides and cytokines in a rabbit model of diabetic neuroischemic wound healing. *J Vasc Surg*, 2013 58(3): p. 766–75.e12. [PubMed: 23755976]
223. Moura LI, et al., Neurotensin-loaded collagen dressings reduce inflammation and improve wound healing in diabetic mice. *Biochim Biophys Acta*, 2014 1842(1): p. 32–43. [PubMed: 24161538]
224. Okonkwo UA and DiPietro LA, Diabetes and Wound Angiogenesis. *Int J Mol Sci*, 2017 18(7).
225. Galkowska H, Wojewodzka U, and Olszewski WL, Low recruitment of immune cells with increased expression of endothelial adhesion molecules in margins of the chronic diabetic foot ulcers. *Wound Repair Regen*, 2005 13(3): p. 248–54. [PubMed: 15953043]
226. Liu ZJ and Velazquez OC, Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. *Antioxid Redox Signal*, 2008 10(11): p. 1869–82. [PubMed: 18627349]
227. Rogers LC, et al., The Charcot foot in diabetes. *J Am Podiatr Med Assoc*, 2011 101(5): p. 437–46. [PubMed: 21957276]
228. Jensen JC, Buresh C, and Norton JA, Lactic acidosis increases tumor necrosis factor secretion and transcription in vitro. *J Surg Res*, 1990 49(4): p. 350–3. [PubMed: 2214745]
229. Andrade SM and Santos IC, Hyperbaric oxygen therapy for wound care. *Rev Gaucha Enferm*, 2016 37(2): p. e59257. [PubMed: 27410674]
230. Ma L, et al., A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. *Ostomy Wound Manage*, 2013 59(3): p. 18–24.
231. Blakytyn R and Jude EB, Altered molecular mechanisms of diabetic foot ulcers. *Int J Low Extrem Wounds*, 2009 8(2): p. 95–104. [PubMed: 19443898]
232. Nguyen DV, Shaw LC, and Grant MB, Inflammation in the pathogenesis of microvascular complications in diabetes. *Front Endocrinol (Lausanne)*, 2012 3: p. 170. [PubMed: 23267348]
233. O'Connor PJ and Ismail-Beigi F, Near-Normalization of Glucose and Microvascular Diabetes Complications: Data from ACCORD and ADVANCE. *Ther Adv Endocrinol Metab*, 2011 2(1): p. 17–26. [PubMed: 23148169]
234. Bianchi C and Del Prato S, Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials. *Rev Diabet Stud*, 2011 8(3): p. 432–40. [PubMed: 22262079]
235. Lim JZ, Ng NS, and Thomas C, Prevention and treatment of diabetic foot ulcers. *J R Soc Med*, 2017 110(3): p. 104–109. [PubMed: 28116957]
236. Sen CK and Roy S, Redox signals in wound healing. *Biochim Biophys Acta*, 2008 1780(11): p. 1348–61. [PubMed: 18249195]
237. Schafer M and Werner S, Oxidative stress in normal and impaired wound repair. *Pharmacol Res*, 2008 58(2): p. 165–71. [PubMed: 18617006]
238. Dunnill C, et al., Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. *Int Wound J*, 2017 14(1): p. 89–96. [PubMed: 26688157]
239. Sen CK, Wound healing essentials: let there be oxygen. *Wound Repair Regen*, 2009 17(1): p. 1–18. [PubMed: 19152646]
240. Bryan N, et al., Reactive oxygen species (ROS)--a family of fate deciding molecules pivotal in constructive inflammation and wound healing. *Eur Cell Mater*, 2012 24: p. 249–65. [PubMed: 23007910]
241. Moseley R, et al., Extracellular matrix metabolites as potential biomarkers of disease activity in wound fluid: lessons learned from other inflammatory diseases? *Br J Dermatol*, 2004 150(3): p. 401–13. [PubMed: 15030321]
242. Golebiewska EM and Poole AW, Platelet secretion: From haemostasis to wound healing and beyond. *Blood Rev*, 2015 29(3): p. 153–62. [PubMed: 25468720]
243. Shah MS and Brownlee M, Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. *Circ Res*, 2016 118(11): p. 1808–29. [PubMed: 27230643]
244. Schramm A, et al., Targeting NADPH oxidases in vascular pharmacology. *Vascul Pharmacol*, 2012 56(5–6): p. 216–31. [PubMed: 22405985]

245. Forrester SJ, et al., Reactive Oxygen Species in Metabolic and Inflammatory Signaling. *Circ Res*, 2018 122(6): p. 877–902. [PubMed: 29700084]
246. Zinkevich NS and Gutterman DD, ROS-induced ROS release in vascular biology: redox-redox signaling. *Am J Physiol Heart Circ Physiol*, 2011 301(3): p. H647–53. [PubMed: 21685266]
247. David JA, et al., The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus. *J Diabetes Res*, 2017 2017: p. 4826724. [PubMed: 28913364]
248. Bitar MS and Al-Mulla F, A defect in Nrf2 signaling constitutes a mechanism for cellular stress hypersensitivity in a genetic rat model of type 2 diabetes. *Am J Physiol Endocrinol Metab*, 2011 301(6): p. E1119–29. [PubMed: 21878664]
249. Soares MA, et al., Restoration of Nrf2 Signaling Normalizes the Regenerative Niche. *Diabetes*, 2016 65(3): p. 633–46. [PubMed: 26647385]
250. Ambrozova N, Ulrichova J, and Galandakova A, Models for the study of skin wound healing. The role of Nrf2 and NF-kappaB. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2017 161(1): p. 1–13. [PubMed: 28115750]
251. Mi Q, et al., Agent-based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1. *Wound Repair Regen*, 2007 15(5): p. 671–82. [PubMed: 17971013]
252. Turner CT, Lim D, and Granville DJ, Granzyme B in skin inflammation and disease. *Matrix Biol*, 2017.
253. Wong SL, et al., Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. *Nat Med*, 2015 21(7): p. 815–9. [PubMed: 26076037]
254. Yipp BG and Kubes P, NETosis: how vital is it? *Blood*, 2013 122(16): p. 2784–94. [PubMed: 24009232]
255. Liu WM, et al., Aging and impaired immunity to influenza viruses: implications for vaccine development. *Hum Vaccin*, 2011 7 Suppl: p. 94–8. [PubMed: 21301210]
256. Frasca D, et al., Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. *J Immunol*, 2008 180(8): p. 5283–90. [PubMed: 18390709]
257. Weksler ME and Szabo P, The effect of age on the B-cell repertoire. *J Clin Immunol*, 2000 20(4): p. 240–9. [PubMed: 10939711]
258. Gibson KL, et al., B-cell diversity decreases in old age and is correlated with poor health status. *Aging Cell*, 2009 8(1): p. 18–25. [PubMed: 18986373]
259. Nomellini V, et al., Dysregulation of neutrophil CXCR2 and pulmonary endothelial icam-1 promotes age-related pulmonary inflammation. *Aging Dis*, 2012 3(3): p. 234–47. [PubMed: 22724082]
260. Tseng CW, et al., Innate immune dysfunctions in aged mice facilitate the systemic dissemination of methicillin-resistant *S. aureus*. *PLoS One*, 2012 7(7): p. e41454. [PubMed: 22844481]
261. Kollmann TR, et al., Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. *Immunity*, 2012 37(5): p. 771–83. [PubMed: 23159225]
262. Madureira P, et al., Inhibition of IL-10 production by maternal antibodies against Group B Streptococcus GAPDH confers immunity to offspring by favoring neutrophil recruitment. *PLoS Pathog*, 2011 7(11): p. e1002363. [PubMed: 22114550]
263. Madureira P, et al., Streptococcus agalactiae GAPDH is a virulence-associated immunomodulatory protein. *J Immunol*, 2007 178(3): p. 1379–87. [PubMed: 17237385]
264. Moore KW, et al., Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol*, 2001 19: p. 683–765. [PubMed: 11244051]
265. Andrade EB, et al., TLR2-induced IL-10 production impairs neutrophil recruitment to infected tissues during neonatal bacterial sepsis. *J Immunol*, 2013 191(9): p. 4759–68. [PubMed: 24078699]
266. Sun CM, et al., Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. *Immunity*, 2005 22(4): p. 467–77. [PubMed: 15845451]
267. Nikoloudi M, et al., Diabetic Foot Infections: Update on Management. *Curr Infect Dis Rep*, 2018 20(10): p. 40. [PubMed: 30069605]

268. Dudek NL, et al., Epitope discovery and their use in peptide based vaccines. *Curr Pharm Des*, 2010 16(28): p. 3149–57. [PubMed: 20687873]
269. Khan MA, et al., Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study. *Scand J Immunol*, 2015 82(1): p. 25–34. [PubMed: 25857850]
270. Yang J, et al., Composite peptide-based vaccines for cancer immunotherapy (Review). *Int J Mol Med*, 2015 35(1): p. 17–23. [PubMed: 25395173]
271. Reed SG, Orr MT, and Fox CB, Key roles of adjuvants in modern vaccines. *Nat Med*, 2013 19(12): p. 1597–608. [PubMed: 24309663]
272. Duthie MS, et al., Use of defined TLR ligands as adjuvants within human vaccines. *Immunol Rev*, 2011 239(1): p. 178–96. [PubMed: 21198672]
273. Tacken PJ, et al., Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. *Blood*, 2011 118(26): p. 6836–44. [PubMed: 21967977]
274. Deleidi M, Jäggle M, and Rubino G, Immune aging, dysmetabolism, and inflammation in neurological diseases. *Front Neurosci*, 2015 9: p. 172. [PubMed: 26089771]
275. Khaitan A and Unutmaz D, Revisiting immune exhaustion during HIV infection. *Curr HIV/AIDS Rep*, 2011 8(1): p. 4–11. [PubMed: 21188556]
276. McKinney EF, et al., T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. *Nature*, 2015 523(7562): p. 612–6. [PubMed: 26123020]
277. Mendes F, et al., The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation. *Biochim Biophys Acta*, 2016 1865(2): p. 168–75. [PubMed: 26868867]
278. Ventura MT, et al., Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. *Clin Mol Allergy*, 2017 15: p. 21. [PubMed: 29259496]
279. Lynch HE, et al., Thymic involution and immune reconstitution. *Trends Immunol*, 2009 30(7): p. 366–73. [PubMed: 19540807]
280. Wong K, et al., Multilineage potential and self-renewal define an epithelial progenitor cell population in the adult thymus. *Cell Rep*, 2014 8(4): p. 1198–209. [PubMed: 25131206]
281. Rode I and Boehm T, Regenerative capacity of adult cortical thymic epithelial cells. *Proc Natl Acad Sci U S A*, 2012 109(9): p. 3463–8. [PubMed: 22331880]
282. Ostan R, et al., Gender, aging and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicine. *Clin Sci (Lond)*, 2016 130(19): p. 1711–25. [PubMed: 27555614]
283. Kautzky-Willer A, Harreiter J, and Pacini G, Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocr Rev*, 2016 37(3): p. 278–316. [PubMed: 27159875]
284. Al-Rubeaan K, et al., Diabetic foot complications and their risk factors from a large retrospective cohort study. *PLoS One*, 2015 10(5): p. e0124446. [PubMed: 25946144]




Figure 1 –. Chronic inflammation is at the center of DFU pathology and is caused by multiple factors that are both interconnected and interdependent. These factors have molecular cues (to the right of the figure) that have cellular consequences (to the left) and, altogether, define the chronic inflammation phenotype.




Figure 2 –.

T-cell expansion is limited by the extent of the glycolytic burst. In diabetic patients, due to chronic hyperglycemia, T-cells expand to greater numbers, reducing the naïve compartment and, consequently, the TCR repertoire diversity. Accumulating effector T-cells increase inflammatory cytokine levels and loss of the naïve pool is not compensated by an increase in thymic output, leading to a probable reduction in T-cell priming efficacy, as seen in elder individuals.




Figure 3 –.

The diabetic foot ulcer pathology has multiple causes that can roughly be divided in three categories (angiopathy, chronic inflammation and neuropathy). All these underlying conditions trigger multiple interconnected effects that lead to an impaired immune response, a poorer tissue remodeling and, consequently, an increased and persistent bacterial wound colonization.